Role of piperine in CNS diseases: pharmacodynamics, pharmacokinetics and drug interactions

被引:17
|
作者
Ren, Tianjing [1 ]
Zuo, Zhong [1 ]
机构
[1] Chinese Univ Hong Kong, Sch Pharm, Hong Kong, Peoples R China
关键词
Piperine; CNS effects; pharmacokinetics; pharmacodynamics; interaction; ENHANCED ORAL BIOAVAILABILITY; BLACK PEPPER; IN-VITRO; TISSUE DISTRIBUTION; LONGUM L; INDUCED NEURODEGENERATION; INDUCED NEUROTOXICITY; URINARY METABOLITE; PUNGENT COMPONENT; MONOAMINE-OXIDASE;
D O I
10.1080/17425255.2019.1672658
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Piperine, the major bioactive component from black pepper, has gained increasing attention for its beneficial effects in the central nervous system (CNS). However, its related pharmacodynamics and brain pharmacokinetics, as well as its interaction with other CNS drugs are lacking, which may hinder its therapeutic and safe use. Areas covered: The current review provides an updated summary on CNS activities of piperine, including anti-epileptic, anti-depressive and neurodegeneration protection effect. The brain pharmacokinetic properties of piperine together with the approaches to enhance its aqueous solubility were summarized. Considering the wide use of black pepper and the well-reported alteration on CYP and transporters by piperine, interactions between piperine and CNS drugs are also illustrated for the first time. Expert opinion: Although the CNS beneficial effects of piperine have been extensively studied in preclinical models, clinical evidence on its CNS application is barely available, which may be attributed to its limited aqueous solubility, unclear pharmacokinetic properties in humans and potential toxicities during long-term use at higher doses. Although beneficial interactions between piperine and certain CNS drugs were often reported in preclinical studies, more mechanistic studies with clinically relevant doses should be conducted to provide guidance on their clinical combination use.
引用
收藏
页码:849 / 867
页数:19
相关论文
共 50 条
  • [1] Mechanisms of drug interactions: pharmacodynamics and pharmacokinetics
    Corrie, Kathryn
    Hardman, Jonathan G.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2014, 15 (07): : 305 - 308
  • [2] Mechanisms of drug interactions: pharmacodynamics and pharmacokinetics
    Corrie, Kathryn
    Hardman, Jonathan G.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2020, 21 (05): : 219 - 222
  • [3] Antidepressant pharmacodynamics, pharmacokinetics, and drug interactions
    Ereshefsky, L
    GERIATRICS, 1998, 53 : S22 - S33
  • [4] Mechanisms of drug interactions: pharmacodynamics and pharmacokinetics
    Corrie, Kathryn
    Hardman, Jonathan G.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2011, 12 (04): : 156 - 159
  • [5] Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug–Drug Interactions
    Tony K. L. Kiang
    Kyle J. Wilby
    Mary H. H. Ensom
    Clinical Pharmacokinetics, 2013, 52 : 487 - 510
  • [6] Mechanisms of drug interactions II: pharmacokinetics and pharmacodynamics
    Rai, Gurjit S.
    Rozario, Christopher J.
    ANAESTHESIA AND INTENSIVE CARE MEDICINE, 2023, 24 (04): : 217 - 220
  • [7] Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interactions
    Kiang, Tony K. L.
    Wilby, Kyle J.
    Ensom, Mary H. H.
    CLINICAL PHARMACOKINETICS, 2013, 52 (07) : 487 - 510
  • [8] The role of unbound drug in pharmacokinetics/pharmacodynamics and in therapy
    Calvo, R
    Lukas, JC
    Rodriguez, M
    Leal, N
    Suarez, E
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (08) : 977 - 987
  • [9] Editorial on Special Issue "Pharmacokinetics, Pharmacodynamics, and Drug Interactions"
    Zhou, Zhu
    PHARMACEUTICS, 2025, 17 (02)
  • [10] The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors
    Xiu, Fangrui
    Rausch, Magdalena
    Gai, Zhibo
    Su, Shanshan
    Wang, Shijun
    Visentin, Michele
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)